Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Synthetic Secretin (ChiRhoStim) vs Vasopressin (Vasostrict)
An educational, source-based comparison of Synthetic Secretin (ChiRhoStim) and Vasopressin (Vasostrict) — how each peptide works, what it's researched for, and what to know before going deeper.
27-amino-acid peptide used to stimulate pancreatic secretions for diagnosis.
Synthetic human secretin that stimulates pancreatic bicarbonate, fluid secretion, and gastrin release — used diagnostically for pancreatic function, gastrinoma evaluation, and ERCP facilitation.
- Pancreatic function testing
- Gastrinoma (Zollinger-Ellison) diagnosis
- ERCP facilitation
- • FDA-approved.
- • Single diagnostic dose; minimal adverse effects.
Endogenous nonapeptide that activates V1 vascular receptors to cause vasoconstriction and V2 renal receptors for water reabsorption. Used to raise blood pressure in catecholamine-resistant shock.
- Septic shock
- Cardiac arrest (historical)
- Diabetes insipidus
- • FDA-approved.
- • Ischemic complications possible at high doses.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Synthetic Secretin (ChiRhoStim) | Secretin stimulation test for gastrinoma | Gastroenterology | 1989 | Established as gold standard provocative test. |
| Vasopressin (Vasostrict) | VASST trial | NEJM | 2008 | Vasopressin added to norepinephrine did not reduce mortality overall but benefited less severe septic shock. |
Side-effect & safety grid
- FDA-approved.
- Single diagnostic dose; minimal adverse effects.
- FDA-approved.
- Ischemic complications possible at high doses.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Synthetic Secretin (ChiRhoStim) vs Vasopressin (Vasostrict) — Key differences
- Class: Synthetic Secretin (ChiRhoStim) is classified as Diagnostic · Gastroenterology, while Vasopressin (Vasostrict) is Vasopressor · Hormonal.
- Primary research focus: Synthetic Secretin (ChiRhoStim) — pancreatic function testing; Vasopressin (Vasostrict) — septic shock.
- Tag: FDA-Approved · Diagnostic vs FDA-Approved · Critical Care.